Latest Tax Incentives News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Explorers led the Materials tape as fresh drill stories and new ground deals pulled buyers into small caps. Big miners still delivered, but the loudest moves came from companies offering investors a near-term catalyst.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

St George Mining has won preferential tax treatment from the Minas Gerais government, cutting development costs for its flagship Araxá Project in Brazil. This support bolsters the company’s ambitions to establish a world-class niobium and rare earths operation.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

Kingsgate Consolidated capped a transformational 2025 with a 344% share price surge and strong cash position, setting ambitious production and exploration targets for 2026.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

PMET Resources has announced a significant capital raise of up to C$130 million through a public offering and a flow-through private placement to advance its Shaakichiuwaanaan critical minerals project in Quebec. The funds will support updated feasibility studies and exploration, aiming to de-risk the path to a Final Investment Decision.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Elixir Energy has reached 2,320 metres in the Lorelle-3 appraisal well and is preparing to drill the reservoir section targeting the Dunk member of the Tinowon Sandstone, with flow testing planned before mid-2026.